A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

CK Life Sciences champions good health and sustainable growth in its business and elsewhere. The company specializes in the development of yeast-based fertilizers and nutritional supplements. Its VitaGain line of nutritional products are sold in Asia. In the US its Vitaquest International (doing business as Garden State Nutritionals) subsidiary is a contract manufacturer of nutritional supplements. Its Australian subsidiaries manufacture commercial and retail fertilizers and gardening products. Other subsidiaries conduct biotech research and development. CK Life Sciences is part of Cheung Kong.

BioTrove, researchers can mine the treasure trove of information encoded in genetic material... and still make it home in time for dinner. The company makes the OpenArray life science research systems that allow scientists to rapidly prepare and test multiple genetic samples at once. The system can perform more than 3,000 genetic tests simultaneously on a single slide and is used by laboratory researchers in gene expression and genotyping analysis. BioTrove was acquired by Life Technologies in late 2009. At the same time, the company's RapidFire sample preparation business was spun off into a new entity named BIOCIUS Life Sciences.

MY Medicare wants to help with your medical care. Mingyuan Medicare Development, or MY Medicare, makes medical diagnostic products for the Chinese market. Its HealthDigit subsidiary produces biochips that detect certain proteins in the body and are used to diagnose and monitor cancer as well as track treatment efficacy. The company has agreements with major Chinese insurance companies, including Taiping Life, China Life, and Ping An Life, that use the chips in medical checkups. MY Medicare also makes a testing kit used to detect cervical cancer. It offers consultation for clinical and technical research and conducts training and seminars from research centers and plants in Shanghai and Beijing.

Ferndale Laboratories makes prescription and over the counter medications, with a primary focus on skin care maladies, including acne, dry skin, eczema, psoriasis, and inflammation. The company also makes topical pain relief creams, surgical adhesives and adhesive removers, and decongestants. Ferndale Laboratories markets its products to physicians and consumers. Ferndale company originally began selling vitamins, tonics, elixirs, and surgical instruments. It was founded in Detroit in 1897 as J. F. Hartz Company, the name it operated under until the mid-1950s when it changed its name to Ferndale Laboratories.

Locus Pharmaceuticals' mission is discovering and developing drug treatments using a technology platform that integrates virtual drug design, medicinal chemistry, and biology. Through its Ansaris division the company researches small molecule treatments for a number of illnesses including HIV, cancer, and inflammatory conditions such as arthritis. The company aims to develop drug candidates in-house and partner with other drugmakers to co-develop drugs. Locus counts Novartis Institute of Biomedical Research and Ono Pharmaceuticals among its partners. The privately-held company is led by president Joan Lau. Investors include Norvartis Bioventures and founding investor, Prism Venture Partners.

Alseres Pharmaceuticals, Inc. was founded in 1972 and is headquartered in Hopkinton, Massachusetts. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.

BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

PharmaGap is trying to close the gap between cancer and cure. Lead drug candidate PhG1 is a protein inhibitor that seeks and inactivates a protein present in unusually elevated levels in many types of cancer, including breast, colon, lung, and neuroblastoma. PharmaGap has commenced with animal testing of PhG1. The company also researches drugs to combat multi-drug-resistant conditions, and immune system resistance testing methods in humans and animals. Founded in 1999, PharmaGap is a spin-off of the National Research Council of Canada, a Canadian biological research firm.

Cephalon, Inc. was founded in 1987 and is headquartered in Frazer, Pennsylvania. Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The company's pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.